title: Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis.
abstract: OBJECTIVE
  Antibiotic prophylaxis has been shown to decrease the incidence of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis and ascites. The aim of this study was to test whether antibiotic prophylaxis for SBP is cost-effective and to compare the costs associated with different patient groups and treatment strategies.
  
  
  METHODS
  A cost-effectiveness analysis was performed using a Markov chain model. The costs incurred during 1-year treatment with prophylactic antibiotics vs. no prophylaxis in patients with cirrhosis and ascites were calculated. The incidence rates of primary and recurrent SBP and the mortality rate of SBP were obtained from the literature. Total direct costs of SBP treatment were determined from the wholesale price of drugs and from disbursements by the Health Care Financing Administration.
  
  
  RESULTS
  Norfloxacin prophylaxis resulted in savings between $2216 and $8545 per patient per year, depending on the patient group studied. Trimethoprim-sulfamethoxazole prophylaxis resulted in savings between $2934 and $9251 per patient per year. The groups that benefited most from prophylaxis were patients with an ascitic fluid total protein concentration of < or = 1 g/dL and those with a previous history of SBP.
  
  
  CONCLUSIONS
  The use of prophylactic antibiotics to decrease the incidence of SBP is a cost-saving strategy in patients with cirrhosis and ascites.
authors.affiliation: Division of Gastroenterology, Department of Veterans Affairs Medical Center, Albuquerque, New Mexico, USA.
authors.forename: J
authors.initials: J
authors.lastname: Inadomi
authors.forename: A
authors.initials: A
authors.lastname: Sonnenberg
mesh_terms: D019072:Antibiotic Prophylaxis / Q000191:economics*; D001201:Ascites / Q000150:complications / Q000382:microbiology; D001424:Bacterial Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006801:Humans; D015994:Incidence; D007297:Inpatients; D008103:Liver Cirrhosis / Q000150:complications / Q000382:microbiology; D008390:Markov Chains; D010538:Peritonitis / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D012051:Reimbursement Mechanisms; D013997:Time Factors; D014481:United States